|
1
|
Xiong J, Xue FS, Yuan YJ, et al:
Cholinergic anti-inflammatory pathway: a possible approach to
protect against myocardial ischemia reperfusion injury. Chin Med J
(Engl). 123:2720–2726. 2010.
|
|
2
|
Naidu BV, Farivar AS, Woolley SM, et al:
Novel broad-spectrum chemokine inhibitor protects against lung
ischemia-reperfusion injury. J Heart Lung Transplant. 23:128–134.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Batista ML Jr, Rosa JC, Lopes RD, et al:
Exercise training changes IL-10/TNF-alpha ratio in the skeletal
muscle of post-MI rats. Cytokine. 49:102–108. 2010. View Article : Google Scholar
|
|
4
|
Shimamoto A, Chong AJ, Yada M, et al:
Inhibition of Toll-like receptor 4 with eritoran attenuates
myocardial ischemia-reperfusion injury. Circulation. 114:I270–I274.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawai T and Akira S: Signaling to
NF-kappaB by Toll-like receptors. Trends Mol Med. 13:460–469. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaisho T and Akira S: Toll-like receptor
function and signaling. J Allergy Clin Immunol. 117:979–987. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arumugam TV, Okun E, Tang SC, et al:
Toll-like receptors in ischemia-reperfusion injury. Shock. 32:4–16.
2009. View Article : Google Scholar
|
|
8
|
Kaczorowski DJ, Nakao A, McCurry KR and
Billiar TR: Toll-like receptors and myocardial
ischemia/reperfusion, inflammation, and injury. Curr Cardiol Rev.
5:196–202. 2009. View Article : Google Scholar
|
|
9
|
Smiley ST, King JA and Hancock WW:
Fibrinogen stimulates macrophage chemokine secretion through
Toll-like receptor 4. J Immunol. 167:2887–2894. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu M, Wang H, Ding A, et al: HMGB1 signals
through Toll-like receptor (TLR) 4 and TLR2. Shock. 26:174–179.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Imai Y, Kuba K, Neely GG, et al:
Identification of oxidative stress and Toll-like receptor 4
signaling as a key pathway of acute lung injury. Cell. 133:235–249.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frantz S, Kobzik L, Kim YD, et al: Toll4
(TLR4) expression in cardiac myocytes in normal and failing
myocardium. J Clin Invest. 104:271–280. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Renaud S and de Lorgeril M: Wine, alcohol,
platelets, and the French paradox for coronary heart disease.
Lancet. 339:1523–1526. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Athar M, Back JH, Tang X, et al:
Resveratrol: A review of preclinical studies for human cancer
prevention. Toxicol Appl Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aluyen JK, Ton QN, Tran T, et al:
Resveratrol: potential as anticancer agent. J Diet Suppl. 9:45–56.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Piotrowska H, Myszkowski K, Ziółkowska A,
et al: Resveratrol analogue 3, 4, 4′, 5-tetramethoxystilbene
inhibits growth, arrests cell cycle and induces apoptosis in
ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol.
263:53–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Afaq F, Adhami VM and Ahmad N: Prevention
of short-term ultraviolet B radiation-mediated damages by
resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol.
186:28–37. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sehirli O, Sakarcan A, Velioğlu-Oğünç A,
et al: Resveratrol improves ifosfamide-induced Fanconi syndrome in
rats. Toxicol Appl Pharmacol. 222:33–41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Y, Nie L, Yin YG, et al: Resveratrol
protects against hyperglycemia-induced oxidative damage to
mitochondria by activating SIRT1 in rat mesangial cells. Toxicol
Appl Pharmacol. 259:395–401. 2012. View Article : Google Scholar
|
|
20
|
Li F, Gong Q, Dong H and Shi J:
Resveratrol, a neuroprotective supplement for Alzheimer’s disease.
Curr Pharm Des. 18:27–33. 2012. View Article : Google Scholar
|
|
21
|
López-Miranda V, Soto-Montenegro ML, Vera
G, et al: Resveratrol: a neuroprotective polyphenol in the
Mediterranean diet. Rev Neurol. 54:349–356. 2012.(In Spanish).
|
|
22
|
Borriello A1, Bencivenga D, Caldarelli I,
et al: Resveratrol: from basic studies to bedside. Borriello A,
Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Zappia V, Della
Ragione F. Cancer Treat Res. 159:167–184. 2014. View Article : Google Scholar
|
|
23
|
Black SC and Rodger IW: Methods for
studying experimental myocardial ischemic and reperfusion injury. J
Pharmacol Toxicol Methods. 35:179–190. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su H, Sun X, Ma H, et al: Acute
hyperglycemia exacerbates myocardial ischemia/reperfusion injury
and blunts cardioprotective effect of GIK. Am J Physiol-Endoc
Metab. 293:E629–E635. 2007. View Article : Google Scholar
|
|
25
|
Speyer CL and Ward PA: Role of endothelial
chemokines and their receptors during inflammation. J Invest Surg.
24:18–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khimenko PL, Bagby GJ, Fuseler J and
Taylor AE: Tumor necrosis factor-alpha in ischemia and reperfusion
injury in rat lungs. J Appl Physiol (1985). 85:2005–2011. 1998.
|
|
27
|
Batista ML, Rosa JC, Lopes RD, et al:
Exercise training changes IL-10/TNF-alpha ratio in the skeletal
muscle of post-MI rats. Cytokine. 49:102–108. 2010. View Article : Google Scholar
|
|
28
|
Zhu J, Liu M, Kennedy RH and Liu SJ:
TNF-alpha-induced impairment of mitochondrial integrity and
apoptosis mediated by caspase-8 in adult ventricular myocytes.
Cytokine. 34:96–105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meldrum DR, Cleveland JC Jr, Cain BS, Meng
X and Harken AH: Increased myocardial tumor necrosis factor-alpha
in a crystalloid-perfused model of cardiac ischemia-reperfusion
injury. Ann Thorac Surg. 65:439–443. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gurevitch J, Frolkis I, Yuhas Y, et al:
Antitumor necrosis factor-alpha improves myocardial recovery after
ischemia and reperfusion. J Am Coll Cardiol. 30:1554–1561. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lefer AM, Ma XL, Weyrich A and Lefer DJ:
Endothelial dysfunction and neutrophil adherence as critical events
in the development of reperfusion injury. Agents Actions Suppl.
41:127–135. 1993.PubMed/NCBI
|
|
32
|
Ma XL, Lefer DJ, Lefer AM and Rothlein R:
Coronary endothelial and cardiac protective effects of a monoclonal
antibody to intercellular adhesion molecule-1 in myocardial
ischemia and reperfusion. Circulation. 86:937–946. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chandrasekar B, Smith JB and Freeman GL:
Ischemia-reperfusion of rat myocardium activates nuclear
factor-KappaB and induces neutrophil infiltration via
lipopolysaccharide-induced CXC chemokine. Circulation.
103:2296–2302. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Otsui K, Inoue N, Kobayashi S, et al:
Enhanced expression of TLR4 in smooth muscle cells in human
atherosclerotic coronary arteries. Heart Vessels. 22:416–422. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ha T, Li Y, Hua F, et al: Reduced cardiac
hypertrophy in Toll-like receptor 4-deficient mice following
pressure overload. Cardiovasc Res. 68:224–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takahashi T: Toll-like receptors and
myocardial contractile dysfunction. Cardiovasc Res. 78:3–4. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hoshino K, Takeuchi O, Kawai T, et al:
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are
hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps
gene product. J Immunol. 162:3749–3752. 1999.PubMed/NCBI
|
|
38
|
Liu YY, Cai WF, Yang HZ, et al: Bacillus
Calmette-Guérin and TLR4 agonist prevent cardiovascular hypertrophy
and fibrosis by regulating immune microenvironment. J Immunol.
180:7349–7357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu P, Hock CE, Nagele R and Wong PY:
Formation of nitric oxide, superoxide, and peroxynitrite in
myocardial ischemia-reperfusion injury in rats. Am J Physiol.
272:H2327–H2336. 1997.PubMed/NCBI
|
|
40
|
Li J, Wu F, Zhang H, et al: Insulin
inhibits leukocyte-endothelium adherence via an Akt-NO-dependent
mechanism in myocardial ischemia/reperfusion. J Mol Cell Cardiol.
47:512–519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li J, Zhang H, Wu F, et al: Insulin
inhibits tumor necrosis factor-alpha induction in myocardial
ischemia/reperfusion: role of Akt and endothelial nitric oxide
synthase phosphorylation. Crit Care Med. 36:1551–1558. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Alcendor RR, Gao S, Zhai P, et al: Sirt1
regulates aging and resistance to oxidative stress in the heart.
Circ Res. 100:1512–1521. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Danz ED, Skramsted J, Henry N, Bennett JA
and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity
through mitochondrial stabilization and the Sirt1 pathway. Free
Radic Biol Med. 46:1589–1597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pillai JB, Isbatan A, Imai S and Gupta MP:
Poly (ADP-ribose) polymerase-1-dependent cardiac myocyte cell death
during heart failure is mediated by NAD+ depletion and reduced
Sir2alpha deacetylase activity. J Biol Chem. 280:43121–43130. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wallerath T, Li H, Gödtel-Ambrust U,
Schwarz PM and Forstermann UA: Blend of polyphenolic compounds
explains the stimulatory effect of red wine on human endothelial NO
synthase. Nitric Oxide. 12:97–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Penumathsa SV, Thirunavukkarasu M, Koneru
S, et al: Statin and resveratrol in combination induces
cardioprotection against myocardial infarction in
hypercholesterolemic rat. J Mol Cell Cardiol. 42:508–516. 2007.
View Article : Google Scholar :
|
|
47
|
Rush JW, Quadrilatero J, Levy AS and Ford
RJ: Chronic resveratrol enhances endothelium-dependent relaxation
but does not alter eNOS levels in aorta of spontaneously
hypertensive rats. Exp Biol Med (Maywood). 232:814–822. 2007.
|
|
48
|
Beher D, Wu J, Cumine S, et al:
Resveratrol is not a direct activator of SIRT1 enzyme activity.
Chem Biol Drug Des. 74:619–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chakrabarty SP, Balaram H and
Chandrasekaran S: Sirtuins: multifaceted drug targets. Curr Mol
Med. 11:709–718. 2011. View Article : Google Scholar : PubMed/NCBI
Danz ED, Skramsted J, Henry N, Bennett JA
and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity
through mitochondrial stabilization and the Sirt1 pathway. Free
Radic Biol Med. 46:1589–1597. 2009. View Article : Google Scholar : PubMed/NCBI
|
